Does Mississippi Medicaid cover GLP-1s for weight loss?
Does Mississippi Medicaid cover GLP-1s for weight loss?
Mississippi Medicaid covers GLP-1 receptor agonists for obesity, subject to prior authorization. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". The published threshold is: Adults 30 or more, or 27 to 29 with at least one weight-related comorbidity — hypertension confirmed by claims history, hyperlipidemia, glucose dysregulation, sleep apnea confirmed by a sleep study, cardiovascular disease or non-alcoholic fatty liver disease. At 12–17 Saxenda needs body weight above 60 kg and a BMI of 30 or more; Wegovy needs a BMI above the 95th percentile for age and sex. On what has to be tried or preferred first: Saxenda or Wegovy only, and one covered obesity product at a time. Last checked 2026-09-05.
What the prior authorization asks for
- BMI threshold
- Adults 30 or more, or 27 to 29 with at least one weight-related comorbidity — hypertension confirmed by claims history, hyperlipidemia, glucose dysregulation, sleep apnea confirmed by a sleep study, cardiovascular disease or non-alcoholic fatty liver disease. At 12–17 Saxenda needs body weight above 60 kg and a BMI of 30 or more; Wegovy needs a BMI above the 95th percentile for age and sex.
- Tried first
- Saxenda or Wegovy only, and one covered obesity product at a time
- To keep it
- A loss of 5% or more of body weight buys another 6 months. A loss of 1 to 4% can buy 3 months, but only where titration was delayed by intolerance, hospitalization or illness, or another non-scale goal was met. Under 1% is a denial. Once at goal or under a BMI of 25 the request moves to maintenance, also 6 months, which asks that weight stay within 15% of the goal BMI. Adherence means three claims in the past 105 days.
- Age
- 12 and over
- Approval runs for
- 6 months, then 6-month renewals
Zepbound is not covered for weight loss. The criteria cover Saxenda and Wegovy as preferred and Xenical as non-preferred, and name Qsymia, phentermine and Evekeo/amphetamine as not covered at all — Qsymia because it is not rebated through CMS.
Both tools fill from these criteria rather than from a template — a prior authorization for Mississippi, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.
Whatever Mississippi decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: Anti-obesity Select Agents PA Criteria , effective 2024-03-12. Read on 2026-09-05. Fee-for-service rules; a managed-care plan in Mississippi can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.